Treatment of non-meningeal cryptococcosis in patients with AIDS
| Autor: | C. Mayaud, Marie-Caroline Meyohas, Jean-Luc Meynard, W. Rozenbaum, J. Frottier, P. Roux, Deluol Am, J.L. Poirot, D. Bollens |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Microbiology (medical)
Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment medicine.disease Gastroenterology Flucytosine Surgery Drug withdrawal Infectious Diseases Internal medicine Amphotericin B Cryptococcosis medicine Adverse effect business Mycosis Fluconazole medicine.drug |
| Zdroj: | Journal of Infection. 33:7-10 |
| ISSN: | 0163-4453 |
| DOI: | 10.1016/s0163-4453(96)92624-9 |
| Popis: | Amphotericin B, alone or combined with flucytosine, is the reference curative treatment for neuromeningeal cryptococcosis associated with the acquired immune deficiency syndrome (AIDS). Treatment of non-meningeal forms is less well standardized. Out of 75 human immunodeficiency virus (HIV)-infected patients with cryptococcosis, 16 had no meningeal involvement. One died before receiving any treatment, another received amphotericine B and recovered, and the remaining 14 received curative therapy with fluconazole (200–400 mg/day); 11 of the latter entered complete remission, while three deteriorated during the first week of treatment but recovered on amphotericin B combined, in two cases, with fluconazole. Only one relapse occurred during maintenance treatment with low-dose fluconazole (100 mg/day). No adverse effects of fluconazole treatment were observed. One of the patients on amphotericin B developed acute renal impairment requiring drug withdrawal. These results suggest that first-line fluconazole therapy is effective and well tolerated in patients with AIDS-associated non meningeal cryptococcosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect